The potential and limitations of personalized medicine in the doctor-patient relationship

Pharmacogenomics

Volumn 4, Issue 6, 2003, Pages 685-687

  Hapgood, Rhydian ^a  

^a Arnold Health Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CODEINE; DRUG METABOLIZING ENZYME; HALOPERIDOL; PRAVASTATIN; SALBUTAMOL; SEROTONIN UPTAKE INHIBITOR; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT;

ASTHMA; BREAST CANCER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; DRUG EFFICACY; EDITORIAL; GENERAL PRACTICE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; PATIENT COUNSELING; PHARMACOGENETICS; PHARMACOGENOMICS; PRESCRIPTION; PRIMARY MEDICAL CARE; SIDE EFFECT;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION; HEALTH CARE AND PUBLIC HEALTH;

HUMANS; INDIVIDUALITY; PHARMACOGENETICS; PHYSICIAN-PATIENT RELATIONS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0242391968     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.6.685.22815     Document Type: Editorial

References (11)

1. Chaix C, Grenier-Sennelier C, Clevenbergh P: Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. J. Acquir. Immune Defic. Syndrome 24, 227-231 (2000).
2. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
3. Hapgood R: A systematised search for evidence of 'real' pharmacogenetic tests. Society of Academic Primary Care Annual Scientific Meeting, Manchester (2003).
4. Nebert D, Ingelman-Sundberg M, Daly A: Genetic epidemiology of environmental toxicity and cancer susceptibility; human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance and nomenclature issues. Drug Metab. Rev. 31, 467-487 (1999).
5. Sindrup SH, Brosen K: The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 5, 335-46 (1995).
6. Drysdale CM, McGraw DW, Stack CB et al.: Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA 97, 10483-10488 (2000).
7. Green SA, Rathz DA, Schuster AJ, Liggett SB: The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur. J. Pharmacol. 421, 141-147 (2001).
8. Kirchheiner J, Brosen K, Dahl ML et al.: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatrica Scandinavica 104, 173-192 (2001).
9. BMA, RPSBG. British National Formulary. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London (2003).
10. Kuivenhoven JA, Jukema JW, Zwinderman AH et al.: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group [see comments]. N. Engl. J. Med. 338, 86-93 (1998).
11. Roses AD: Pharmacogenetics and the practice of medicine. Nature 405, 857-865 (2000).